Affitech-Identified Fully Human Anti-VEGF Antibody Candidate Is As Effective As Avastin(R) In Preclinical Cancer Models
Affitech AS, the human antibody therapeutics company announced that its partner, Peregrine Pharmaceuticals, has reported that its anti-VEGF antibody R84, an antibody identified by Affitech, selectively blocks the interaction of vascular endothelial growth factor (VEGF) to VEGF receptor 2
Original post by Women’s Health / Gynecology News From Medical News Today
Related Articles
New documents Confirms That A Selective, Fully Human Anti-VEGF Antibody Being Developed By Peregrine Is As Effective As Avastin(R) In Preclinical Models Affitech Participates In The Newly Formed Norwegian Stem Cell-Based Tumour Therapy Center Preclinical Study Published In Cancer Research Demonstrates Anti-Tumor Activity Of Micromet’s BiTE Antibody At Well Tolerated Doses Lpath Demonstrates Preclinical Efficacy Of Lpathomab(TM) And Initiates Humanization Process Is Earlier Detection Of Cancers Such As Glioma Possible?
